GenScript Biotech & REMD Biotherapeutics Inc. Reached a Strategic Collaboration to Develop Several Bispecific Antibodies

01:57 EDT 5 May 2019 | Synbiobeta

Apr. 26, 2019 Nanjing, China · Camarillo, California, US —— GenScript Biotech Corporation, a world leading bio-pharmaceutical CDMO company, has entered into an exclusive strategic drug development cooperation with REMD Biotherapeutics Inc. (hereinafter REMD) on several bispecific antibodies. According to the Agreement, GenScript will allow REMD to use its SMAB (Single-Domain Antibody fused to Monoclonal […]

More From BioPortfolio on "GenScript Biotech & REMD Biotherapeutics Inc. Reached a Strategic Collaboration to Develop Several Bispecific Antibodies"